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Background: Acute behavioural disturbance (ABD) is a common problem in psychiatry and both physical restraint
and involuntary parenteral sedation are often required to control patients. Although guidelines are available, clinical
practice is often guided by experience and there is little agreement on which drugs should be first-line treatment
for rapid tranquilisation. This study aimed to investigate sedation for ABD in an acute mental healthcare unit,
including the effectiveness and safety of high dose sedation.
Methods: A prospective study of parenteral sedation for ABD in mental health patients was conducted from July
2010 to June 2011. Drug administration (type, dose, additional doses), time to sedation, vital signs and adverse
effects were recorded. High dose parenteral sedation was defined as greater than the equivalent of 10 mg
midazolam, droperidol or haloperidol (alone or in combination), compared to patients receiving 10 mg or less
(normal dose). Effective sedation was defined as a fall in the sedation assessment tool score by two or a score of
zero or less. Outcomes included frequency of adverse drug effects, time to sedation/tranquilisation and use of
additional sedation.
Results: Parenteral sedation was given in 171 cases. A single drug was given in 96 (56%), including droperidol (74),
midazolam (19) and haloperidol (3). Effective sedation occurred in 157 patients (92%), and the median time to
sedation was 20 min (Range: 5 to 100 min). The median time to sedation for 93 patients receiving high dose
sedation was 20 min (5-90 min) compared to 20 min (5-100 min; p = 0.92) for 78 patients receiving normal dose
sedation. Adverse effects occurred in 16 patients (9%); hypotension (14), oxygen desaturation (1), hypotension and
oxygen desaturation (1). There were more adverse effects in the high dose sedation group compared to the normal
dose group [11/93 (12%) vs. 5/78 (6%); p = 0.3]. Additional sedation was given in 9 of 171 patients (5%), seven in
the high dose and two in the normal dose groups.
Conclusions: Large initial doses of sedative drugs were used for ABD in just over half of cases and additional
sedation was uncommon. High dose sedation did not result in more rapid or effective sedation but was associated
with more adverse effects.
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Table 1 Sedation Assessment Tool: SAT
SCORE RESPONSIVENESS SPEECH
+3 Combative, violent, out of control Continual loud
outbursts
+2 Very anxious and agitated Loud outbursts
+1 Anxious and restless Normal
0 Responds easily to name, speaks
in normal tone
Normal




-2 Physical stimulation Few recognisable
words
-3 No response to stimulation Nil
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Acute behavioural disturbance (ABD) is a common occur-
rence in the healthcare setting of acute psychiatry [1,2].
Both physical restraint and involuntary parenteral sedation
are often required to control patients with ABD. The over-
all goal is to achieve rapid sedation or tranquilisation to
prevent injury to the patient, other patients or staff, whilst
minimizing adverse drug effects. When all other strategies
such as verbal de-escalation have failed to manage the
ABD, parenteral sedation is recommended to prevent dis-
tress and reduce harm [3-5].
Although many prescriptive guidelines are available,
clinical practice is often primarily guided by experience
as there is little agreement on which drugs should be
used as first-line treatment for rapid tranquilisation.
There is general consensus in the literature that benzo-
diazepines alone, an antipsychotic alone or a combin-
ation of the two are the first line agents for sedation in
patients with ABD [1]. Clinical practice guidelines are
reasonably consistent in recommending doses of 5 mg
to 10 mg of a typical antipsychotic and 5 to 10 mg of
midazolam or diazepam (or 2 mg of lorazepam) when
used in combination [1,6-9]. However, larger doses are
often used, exceeding doses recommended in many clin-
ical practice guidelines [1,9] and the recommendations
of the British National Formulary [10]. This is acknowl-
edged by expert clinical opinion [1,11,12].
This study aimed to investigate the types, doses and
frequency of drugs used for sedation of ABD in an acute
mental health unit, and the frequency of adverse drug ef-
fects. We hypothesized that larger doses of sedation
might increase the frequency of adverse effects and may
reduce the requirement for additional sedation.
Methods
This was a prospective observational study of patients
with ABD in an acute mental healthcare unit who re-
quired parenteral sedation and physical restraint to pro-
tect themselves and/or others. We measured the time to
sedation, frequency of adverse effects and use of add-
itional sedation.
The study was undertaken from July 2010 to June 2011
in an eight bed acute mental healthcare unit in a tertiary
specialist mental health facility with a 90% occupancy rate.
Ethics approval was obtained from the local Human
Research Ethics Committee. Consent was waived because
of the requirement for immediate treatment and patients’
lack of decision-making capacity to consent to medical
treatment being given as a duty of care.
The study included all patients administered parenteral
sedation for ABD in the acute mental healthcare unit. Ad-
missions to the unit are from the psychiatric emergency
care center and are referred from general practitioners, re-
gional hospitals or other units within the institution.All patients with ABD in the acute mental healthcare unit
who did not calm with verbal de-escalation or oral medica-
tion and who required physical restraint and parenteral sed-
ation were included. The choice of drug or drugs and the
doses administered were determined by the treating clin-
ician. Parenteral sedation was given by initially physically
restraining the patient to administer the medications. The
patient was then put in a seclusion room and was not mech-
anically restrained. All patients were involuntary admissions.
Vital signs were recorded every 10 minutes for the first
hour then half hourly until the patient settled. A number
of the observations were recorded remotely, including
the respiratory rate and the level of agitation. Remote
observations were commenced from the onset of the
ABD until it was considered safe to approach the patient
and record vital signs including heart rate, blood pres-
sure, oxygen saturation and respiratory rate. The level of
sedation and agitation was recorded using the sedation
assessment tool (SAT; Table 1) [13]. The SAT scores the
patient from +3 (physically violent) to -3 (unconscious)
and allows rapid assessment before and after sedative
medication is given. A initial score of +2 or +3 was re-
quired and almost always reported in patients requiring
physical restraint and parental sedation. We have previ-
ously defined effective rapid sedation or tranquilisation
as a fall in the score by two levels or a score of zero or
less [13-15]. An additional dose of sedative medication was
encouraged by the senior medical staff after 30 minutes if
there was no response to the first drug given. If the patient
did not sedate after 120 minutes they were considered to
have failed sedation. The patient was observed for extra-
pyramidal side-effects and any additional medications were
recorded.
At the commencement of the study a previously devel-
oped ABD chart was introduced into the acute mental
healthcare unit. The ABD chart is part of the medical rec-
ord and is used to record the level of agitation and sed-
ation with the SAT, vital signs and any adverse effects that
occur. The use of the form allowed the simultaneous use
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clinical care of the patient. The following data were then
extracted from the ABD chart and medical record: age,
sex, medication used including time of administration,
dose and additional sedation given. For this study high
dose parenteral sedation was defined as a dose greater
than the equivalent of 10 mg of midazolam, 10 mg of
droperidol or 10 mg of haloperidol, whether as a single
agent or a combination of these three drugs. This was
based on a controlled trial that compared droperidol
(10 mg) versus midazolam (10 mg), versus the combin-
ation of droperidol (5 mg) and midazolam (5 mg) [14],
and the fact that these were the commonest drugs used in
the institution during the study. Patients receiving equal
to or less than 10 mg of these three drugs were classified
as the normal dose group.
The outcomes for this study were the time to sed-
ation/tranquilisation defined as a fall in the SAT score
by two levels or a score of zero or less; the proportion of
patients with adverse drug effects defined as a respira-
tory rate less than 12 breaths per min, systolic blood
pressure less than 90 mmHg, oxygen saturation less than
90% or the presence of extrapyramidal side-effects; and
the use of additional sedation. The outcomes were com-
pared between patients receiving high dose parenteral
sedation and those receiving normal or a lower dose.
Medians and interquartile ranges (IQR) are reported for
all continuous variables. Percentages are reported for di-
chotomous outcomes with 95% confidence intervals (CI).
Dichotomous outcomes were compared using Fisher’s
exact test. All analyses and graphics were done in
GraphPad Prism version 5.03 for Windows, GraphPad
Software, San Diego California USA, www.graphpad.com.
Results
There were 171 occasions of patients with ABD requiring
parenteral sedation in 95 patients during the 12 monthTable 2 Details of the initial drug type and dose for all 171 e
sedation for each drug type/combination
Drug type Initial drug Dose range (m
Droperidol 74 5 to 30
Midazolam 19 5 to 15
Haloperidol 3 10
Midazolam + droperidol 61 5 to 15 +
5 to 25
Midazolam + haloperidol 12 5 to 10 + 10
Droperidol/lorazepam 1 2.5 + 2
Lorazepam 1 2period. The median age of the patients was 40 years (15 to
80 yr) and 121 patients were male. The median SAT score
prior to sedation was 2 (IQR: 2 to 3). A single drug was
administered on 97 occasions and was most commonly
droperidol (74; median dose 10 mg; range 5 to 30 mg),
then midazolam (19; median dose 10 mg; range 5 to
15 mg) and haloperidol (3; all 10 mg). Combinations of
drugs were used in the remaining 75 occasions with the
combination of droperidol (10 mg) and midazolam
(10 mg) being the most common on 61 occasions. Table 2
lists the different combinations of drugs, the range of drug
doses and the frequency used. Ninety three patients (54%)
were given more than the equivalent of 10 mg droperidol/
midazolam (high dose parenteral sedation), and the major-
ity of these were patients were given 10 mg of either
droperidol or haloperidol in combination with 10 mg of
midazolam (Table 2). There was no significant difference
in age, sex and initial SAT score between patients receiv-
ing high dose sedation versus normal sedation dose.
Effective sedation was achieved in 157 patients, and
the median time to sedation was 20 min (IQR: 15 to
35 min; Range: 5 to 100 min). The median time to
sedation for high dose sedation was 20 minutes (IQR: 18
to 35 min; Range: 5 to 100 min), and 20 minutes (IQR:
11 to 40 min; Range: 5 to 90 min) for normal dose
sedation (Figure 1). The remaining 14 patients were not
sedated with the initial dose of sedation; eight given high
dose and six given normal dose.
Adverse effects occurred in 16 patients (9%), including
hypotension (14), oxygen de-saturation (1), hypotension
and oxygen de-saturation (1) (Table 2). The frequency of
adverse effects was higher for the high dose group com-
pared to the normal dose group [11/93 (12%) vs. 5/78
(6%); p = 0.3] (Figure 2). Of the 14 patients not sedated
none received additional sedation. Additional sedation
was administered to 9 of the 171 patients (5%), seven in
the high dose group and two in the normal dose group.pisodes and the adverse effects and median time to
g) Adverse effects Median time to










Figure 1 The time to sedation for the high dose group
compared to the low dose group.
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The study found that large initial doses of parenteral
sedation are commonly used in the treatment of ABD in
the acute mental health setting. The higher dose paren-
teral sedation was not associated with a shorter time to
sedation, but was associated with a higher frequency of
adverse effects. Of the 16 adverse drug effects that oc-
curred, almost two-thirds occurred in the patients who
received high dose parenteral sedation. The study also
showed that the additional sedation was rarely used in
both groups.
The high dose parenteral sedation of greater than
10 mg of droperidol, haloperidol or midazolam alone or
in combination, is more than the recommended dose in
clinical practice guidelines [1,9]. It is also greater than
the doses from randomized controlled trials in the acute
psychiatric setting where initial doses ranged from 5 to
10 mg of droperidol or midazolam/haloperidol or
equivalent amounts of other sedative drugs [16-19].
Unfortunately there is a lack of good evidence to sup-







Figure 2 Adverse effects based on high or normal dose sedation andtranquilisaton of ABD in the acute psychiatry setting.
This may be in part due to the difficulties in obtaining eth-
ics approval to study this vulnerable patient population
and the need to obtain consent from patients without the
capacity to consent. Many trials only include patients with
written consent [20,21] and require co-operation from the
patients prior to recruitment in the form of performing
tests and obtaining blood samples [21] which is rarely pos-
sible due to safety issues in patients with ABD. This means
that trials in the mental health setting rarely include the
most agitated patients and the treatment of this difficult
group of patients with ABD is often guided by clinical ex-
perience rather than evidence from clinical trials. This
may explain the disparity between what is in clinical
guidelines based on the literature and what actually hap-
pens with the sedation of ABD in the clinical setting.
A difference found in this study compared to other
studies of management of ABD in mental health [16-22]
was the large initial doses of medication administered to
patients, which was often a combination of medications.
Combinations of medications, most commonly a benzo-
diazepine and an antipsychotic, reflects a common strat-
egy in the acute psychiatry setting [6,23]. Although the
literature supports the strategy of combining agents, it
recommends that lower doses of each medication are
used to reduce the risk of adverse effects [6,23]. How-
ever, in this study the use of combinations of drugs
resulted in a larger total dose being administered in
most patients. Importantly, the larger dose did not result
in more rapid sedation, but did result in an increased
frequency of adverse effects (Figure 2).
The frequency of adverse effects in this study may be
an underestimate of the true frequency because of the
difficulties in obtaining a complete set of vital signs in
these dangerous patients. The inability to have immedi-
ate access to the patient due to the level of agitation
makes the recording of vital signs and the detection of







the types of adverse effects.
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recorded from outside the seclusion room until the pa-
tient was sedated sufficiently to allow the recording of
blood pressure and oxygen saturations.
Additional sedation was rarely used in this study which
is most likely due to the danger associated with ap-
proaching a violent patient on a second occasion once they
are in seclusion. In this study 14 patients were not sedated
after the initial dose, but additional sedation was only ad-
ministered in nine patients. This differs to studies of sed-
ation of ABD in the emergency department where 26% to
45% of patients are given additional sedation [14,24].
There were a number of limitations to the study in-
cluding the non-randomised nature of the sample. This
may have introduced bias because patients with more se-
vere ABD may have been more likely to be given high
dose sedation. However, there was no difference in the
initial SAT score between patients in the high and nor-
mal dose sedation groups. The overall frequency of ad-
verse effects in the study was low so the difference
between the high and normal dose groups did not reach
statistical significance. A larger study is required to con-
firm this finding.Conclusion
The study has shown that large initial doses of sedative
drugs were used in just over half of cases of ABD in the
mental health setting. High dose sedation did not result
in more rapid or effective sedation than normal or lower
doses of sedation. However, high dose sedation was asso-
ciated with more adverse effects. Additional sedation
was uncommon in all patients. This suggests there is no
benefit and potential risk if large initial doses of sedation
are given to patients with ABD. Doses recommended by
the majority of guidelines should be used and larger
doses of single agents or combinations of drugs should
be avoided.
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